Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23323905)

1.

Antiretroviral therapy in early HIV infection.

Walker BD, Hirsch MS.

N Engl J Med. 2013 Jan 17;368(3):279-81. doi: 10.1056/NEJMe1213734. No abstract available.

2.

Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial.

Boué F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, Goujard C, Lancar R, Costagliola D.

AIDS. 2011 Jan 2;25(1):115-8. doi: 10.1097/QAD.0b013e328340a1e7.

PMID:
20962614
3.

Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.

Kaufmann GR, Elzi L, Weber R, Furrer H, Giulieri S, Vernazza P, Bernasconi E, Hirschel B, Battegay M; Swiss HIV Cohort Study.

AIDS. 2011 Feb 20;25(4):441-51. doi: 10.1097/QAD.0b013e3283430013.

PMID:
21206265
4.

Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.

Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, Stahmer I, van Lunzen J, Lichterfeld M, Gao X, Allen TM, Carrington M, Walker BD, Rockstroh JK, Altfeld M.

J Infect Dis. 2006 Sep 15;194(6):734-9. Epub 2006 Aug 15.

5.

Early versus deferred antiretroviral therapy for HIV.

Hernán MA, Robins JM.

N Engl J Med. 2009 Aug 20;361(8):822-3; author reply 823-4. No abstract available.

PMID:
19701984
6.

Early versus deferred antiretroviral therapy for HIV.

Buchbinder SP, Jain V.

N Engl J Med. 2009 Aug 20;361(8):822; author reply 823-4. doi: 10.1056/NEJMc091170. No abstract available.

7.

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research.

Bae JW, Guyer W, Grimm K, Altice FL.

AIDS. 2011 Jan 28;25(3):279-90. doi: 10.1097/QAD.0b013e328340feb0. Review.

PMID:
21239892
8.

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B.

AIDS. 2003;17 Suppl 4:S85-96. Review. No abstract available.

PMID:
15080184
9.

Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.

Albuquerque AS, Foxall RB, Cortesão CS, Soares RS, Doroana M, Ribeiro A, Lucas M, Antunes F, Victorino RM, Sousa AE.

Clin Immunol. 2007 Oct;125(1):67-75. Epub 2007 Aug 9.

PMID:
17692571
10.

Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy.

Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, Ho YS, Saksena NK, Hoy J, Crowe SM, Cameron PU, Lewin SR.

J Infect Dis. 2010 Dec 1;202(11):1738-48. doi: 10.1086/656721. Epub 2010 Oct 27.

11.

Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment.

Killian MS, Fujimura SH, Hecht FM, Levy JA.

AIDS. 2006 Jun 12;20(9):1247-52.

PMID:
16816552
12.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.

J Infect Dis. 2009 Nov 15;200(10):1490-7. doi: 10.1086/644598.

13.

[What happens when antiretroviral treatment is interrupted in clinical practice?].

Marcos Sánchez F, Albo Castaño I, Joya Seijo D, del Valle Loarte P, Martín Barranco MJ.

An Med Interna. 2005 Oct;22(10):502. Spanish. No abstract available.

PMID:
16411308
14.

Editorial commentary: Under the spell of the red queen.

Lange JM.

Clin Infect Dis. 2013 Oct;57(7):1048-50. doi: 10.1093/cid/cit425. Epub 2013 Aug 6. No abstract available.

15.

Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults.

González R, Castro P, García F, Plana M, Bayas JM, Lafuente S, Serrano B, Mora B, Argelich R, Gatell JM, Vilella A.

HIV Med. 2010 Sep;11(8):535-9. doi: 10.1111/j.1468-1293.2010.00830.x. Epub 2010 Apr 13.

PMID:
20408890
16.

Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.

Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, Carr A, Cooper DA.

AIDS. 2000 Dec 1;14(17):2643-51.

PMID:
11125882
17.

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

Lugli E, Pinti M, Nasi M, Troiano L, Prada N, Mussini C, Borghi V, Esposito R, Cossarizza A.

Int J Immunogenet. 2005 Oct;32(5):269-71.

PMID:
16164692
18.

Lower mortality and earlier start of combination antiretroviral therapy in patients tested repeatedly for HIV than in those with a positive first test.

Gras L, van Sighem A, Bezemer D, Smit C, Wit F, de Wolf F; ATHENA national observational cohort study.

AIDS. 2011 Mar 27;25(6):813-8. doi: 10.1097/QAD.0b013e3283454cd7.

PMID:
21330906
19.

[Optimal time for antiretroviral therapy of HIV infection: NA-ACCORD (North American AIDS cohort collaboration on research and design)].

Jensen B, Nitschmann S, Häussinger D.

Internist (Berl). 2009 Dec;50(12):1425-6. doi: 10.1007/s00108-009-2523-7. German. No abstract available.

PMID:
19902153
20.

CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.

Seminari E, De Silvestri A, Boschi A, Tinelli C.

AIDS Rev. 2008 Oct-Dec;10(4):236-44.

PMID:
19092979
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk